JP2017507158A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507158A5
JP2017507158A5 JP2016555713A JP2016555713A JP2017507158A5 JP 2017507158 A5 JP2017507158 A5 JP 2017507158A5 JP 2016555713 A JP2016555713 A JP 2016555713A JP 2016555713 A JP2016555713 A JP 2016555713A JP 2017507158 A5 JP2017507158 A5 JP 2017507158A5
Authority
JP
Japan
Prior art keywords
hypoplasia
congenital
glaucoma
crystalline salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507158A (ja
JP6946001B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/018889 external-priority patent/WO2015134711A1/en
Publication of JP2017507158A publication Critical patent/JP2017507158A/ja
Priority to JP2019211430A priority Critical patent/JP7335795B2/ja
Publication of JP2017507158A5 publication Critical patent/JP2017507158A5/ja
Priority to JP2021111631A priority patent/JP2021165299A/ja
Application granted granted Critical
Publication of JP6946001B2 publication Critical patent/JP6946001B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555713A 2014-03-06 2015-03-05 薬学的組成物、および1,2,4−オキサジアゾール安息香酸の塩 Expired - Fee Related JP6946001B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019211430A JP7335795B2 (ja) 2014-03-06 2019-11-22 薬学的組成物、および1,2,4-オキサジアゾール安息香酸の塩
JP2021111631A JP2021165299A (ja) 2014-03-06 2021-07-05 薬学的組成物、および1,2,4−オキサジアゾール安息香酸の塩

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461949052P 2014-03-06 2014-03-06
US61/949,052 2014-03-06
US201462009111P 2014-06-06 2014-06-06
US62/009,111 2014-06-06
PCT/US2015/018889 WO2015134711A1 (en) 2014-03-06 2015-03-05 Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019211430A Division JP7335795B2 (ja) 2014-03-06 2019-11-22 薬学的組成物、および1,2,4-オキサジアゾール安息香酸の塩
JP2021111631A Division JP2021165299A (ja) 2014-03-06 2021-07-05 薬学的組成物、および1,2,4−オキサジアゾール安息香酸の塩

Publications (3)

Publication Number Publication Date
JP2017507158A JP2017507158A (ja) 2017-03-16
JP2017507158A5 true JP2017507158A5 (cg-RX-API-DMAC7.html) 2020-01-30
JP6946001B2 JP6946001B2 (ja) 2021-10-06

Family

ID=54055864

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016555713A Expired - Fee Related JP6946001B2 (ja) 2014-03-06 2015-03-05 薬学的組成物、および1,2,4−オキサジアゾール安息香酸の塩
JP2019211430A Active JP7335795B2 (ja) 2014-03-06 2019-11-22 薬学的組成物、および1,2,4-オキサジアゾール安息香酸の塩
JP2021111631A Ceased JP2021165299A (ja) 2014-03-06 2021-07-05 薬学的組成物、および1,2,4−オキサジアゾール安息香酸の塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019211430A Active JP7335795B2 (ja) 2014-03-06 2019-11-22 薬学的組成物、および1,2,4-オキサジアゾール安息香酸の塩
JP2021111631A Ceased JP2021165299A (ja) 2014-03-06 2021-07-05 薬学的組成物、および1,2,4−オキサジアゾール安息香酸の塩

Country Status (10)

Country Link
US (3) US9873677B2 (cg-RX-API-DMAC7.html)
EP (1) EP3113619A4 (cg-RX-API-DMAC7.html)
JP (3) JP6946001B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230024431A (cg-RX-API-DMAC7.html)
CN (3) CN106455571A (cg-RX-API-DMAC7.html)
CA (2) CA2942147C (cg-RX-API-DMAC7.html)
EA (1) EA032779B1 (cg-RX-API-DMAC7.html)
IL (1) IL247653B (cg-RX-API-DMAC7.html)
TW (2) TWI636978B (cg-RX-API-DMAC7.html)
WO (1) WO2015134711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235115C1 (en) 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
UA99600C2 (en) * 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
TW201729807A (zh) 2015-10-30 2017-09-01 Ptc治療公司 用於治療癲癇的方法
EP3377476B1 (en) * 2015-11-16 2022-10-26 PTC Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
CA3048202A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by inhibition of nonsense mediated decay
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
WO2019101709A1 (en) 2017-11-23 2019-05-31 Universita' Degli Studi Di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
CN109678715B (zh) * 2018-11-28 2019-11-12 中国药科大学 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途
US10637694B1 (en) 2018-12-21 2020-04-28 At&T Intellectual Property I, L.P. Reduction and/or mitigation of spatial emissions in multi-antenna wireless communication systems for advanced networks
KR20210151131A (ko) 2019-04-10 2021-12-13 피티씨 테라퓨틱스, 인크. 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법
WO2022128876A1 (en) * 2020-12-14 2022-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Ataluren eye drop formulation
US20250255816A1 (en) * 2022-04-18 2025-08-14 Vanderbilt University Polysulfide microparticles and uses thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (cg-RX-API-DMAC7.html) 1962-04-17
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4016170A (en) 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4166732A (en) 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
EP0853626A1 (en) 1995-09-07 1998-07-22 Novartis AG Substituted phosphinic compounds and their use as pharmaceuticals
WO1997041105A1 (en) 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Novel heterocycle-substituted benzene derivatives and herbicides
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下3▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
ES2329739T3 (es) 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
AU9647998A (en) 1997-10-27 1999-05-17 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
IL139187A0 (en) 1998-04-23 2001-11-25 Cortech Inc Cysteine protease inhibitors
CA2346689A1 (en) 1998-10-08 2000-04-20 Gregor James Macdonald Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
EP1119568B1 (en) 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
BR9916488A (pt) 1998-12-23 2001-10-09 Smithkline Beecham Corp Inibidores de protease
WO2000058280A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
AU3196200A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
WO2000058304A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
AU4537900A (en) 1999-05-17 2000-12-05 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
US6498151B2 (en) 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
AU2001248765A1 (en) 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
DZ3347A1 (fr) 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
BR0209054A (pt) 2001-04-19 2004-04-20 Bayer Ag Arilsulfonamidas como agentes antivirais
US7041685B2 (en) 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
EP1405636A4 (en) 2001-06-26 2009-04-15 Takeda Pharmaceutical FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
CN1691944A (zh) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体-5调节剂的噁二唑
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
JP2006521344A (ja) 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのcetp阻害剤としての1,2,4−置換1,2,3,4−テトラヒドロ−および1,2−ジヒドロ−キノリンおよび1,2,3,4−テトラヒドロ−キノキサリン誘導体
EP4101846B1 (en) * 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
JP5255183B2 (ja) 2003-09-04 2013-08-07 ウォックハート リミテッド ベンゾキノリジン−2−カルボン酸アルギニン塩四水和物
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005097096A1 (en) * 2004-03-31 2005-10-20 Pharmacia & Upjohn Company Llc A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders
JP2008515992A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス,インコーポレーテッド 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
CN101193632A (zh) * 2005-04-08 2008-06-04 Ptc医疗公司 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物
AU2006235115C1 (en) * 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
EP2387995A1 (en) * 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
NZ598012A (en) * 2006-09-08 2013-08-30 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids
US8101641B2 (en) 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
UA99600C2 (en) 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
KR20170100072A (ko) * 2006-10-12 2017-09-01 피티씨 테라퓨틱스, 인크. 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
CN101970420B (zh) 2007-10-04 2014-09-24 默克雪兰诺有限公司 噁二唑衍生物
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2234625B8 (en) 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
MX2010010300A (es) * 2008-03-19 2010-10-26 Osi Pharm Inc Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
WO2010008831A2 (en) 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
NZ605452A (en) 2008-07-14 2014-05-30 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
AU2009302478B2 (en) 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
WO2011072281A1 (en) * 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
EP2559443A1 (en) * 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
WO2014153643A1 (en) * 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
WO2015188037A1 (en) 2014-06-06 2015-12-10 Ptc Therapeutics, Inc. Methods of treatment using a 1,2,4-oxadiazole benzoic acid

Similar Documents

Publication Publication Date Title
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
JP6397472B2 (ja) ドライアイ症候群の治療のための医薬組成物
JP6100782B2 (ja) 緑内障および高眼圧症を治療するための活性剤の徐放送達
Whitson et al. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride
JP2023153926A (ja) 交差架橋剤、及び関連する方法
MX2009000885A (es) Soluciones oftalmicas.
JP2018529693A5 (cg-RX-API-DMAC7.html)
US20120122976A1 (en) Phosphate-free pharmaceutical composition for the treatment of glaucoma
US20250041211A1 (en) Ophthalmic preparation and application thereof in treatment of presbyopia
JP2013534527A (ja) コンタクトレンズ乳頭結膜炎及びアレルギー性眼疾患の予防及び処置のための組成物
JP2017535578A (ja) 安定したオメガ−3眼科用組成物
TWI759276B (zh) 淚液油層穩定劑及含有該淚液油層穩定劑的滴眼劑
Oh et al. Comparison of clinical outcomes of same-size grafting between deep anterior lamellar keratoplasty and penetrating keratoplasty for keratoconus
JP2009501726A (ja) 眼科学的活性剤の製剤とその投与の方法
US20090239836A1 (en) Multifunctional Ophthalmic Compositions
CN108261390A (zh) 一种布林佐胺溴莫尼定滴眼液及其制备方法
EP2249871A2 (en) Opthalmic composition
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
CN101491525A (zh) 四氢嘧啶在制备治疗干眼症药物中的应用
JP2020525416A5 (cg-RX-API-DMAC7.html)
HRP20211589T1 (hr) Uporaba proteoglikana 4 (prg4) za poboljšanje dinamičke vizuelne oštrine i aberacija višeg reda
US20210259962A1 (en) Methods for improving vision
KR102268002B1 (ko) 효과 지속성 점안제 조성물
CN110200904B (zh) 一种降眼压缓释滴眼组合物及其制备方法
CA2761740A1 (en) Phosphate-free pharmaceutical composition for the treatment of glaucoma